The European Cancer Organisation welcomed the commitment to producing a new EU Pharmaceutical Strategy, and the accompanying commitment to public consultation on its content.
The European Cancer Organisation's response articulates seven (7) key recommendations:
Ensure the new EU Pharmaceutical Strategy is ambitious and comprehensive
Remodel the incentive structures further towards value and outcomes, and support innovation in all areas of treatment and care
Resolve the current political impasse on the HTA cooperation proposal
Leverage data and new tools in a more coherent and powerful way
Reduce bureaucracy in the clinical trial landscape
Urgently address the medicines shortages crisis
Work with medical and healthcare professional societies and patient associations as equal partners in creating the best possible changes
Read the Response here.